Cargando…

Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer

SIMPLE SUMMARY: The PAM50 risk of recurrence (ROR) score is predictive of the risk of distant recurrence and the benefits of adjuvant therapy in early breast cancer. The Prosigna assay utilizes RNA from tumor cells selected via macrodissection of formalin-fixed, paraffin-embedded (FFPE) tissue secti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lien, Tonje G., Ohnstad, Hege Oma, Lingjærde, Ole Christian, Vallon-Christersson, Johan, Aaserud, Marit, Sveli, My Anh Tu, Borg, Åke, OSBREAC, on behalf of, Garred, Øystein, Borgen, Elin, Naume, Bjørn, Russnes, Hege, Sørlie, Therese
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657125/ https://www.ncbi.nlm.nih.gov/pubmed/34885228 http://dx.doi.org/10.3390/cancers13236118

Ejemplares similares

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
por: Ohnstad, Hege O., et al.
Publicado: (2017)

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
por: Tekpli, Xavier, et al.
Publicado: (2019)

Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
por: Rye, Inga Hansine, et al.
Publicado: (2021)

RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
por: Staaf, Johan, et al.
Publicado: (2022)

The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
por: Molloy, Timothy J, et al.
Publicado: (2011)

Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
por: Veerla, Srinivas, et al.
Publicado: (2023)

The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
por: Silwal-Pandit, Laxmi, et al.
Publicado: (2015)

The multitude of molecular analyses in cancer: the opening of Pandora’s box
por: Russnes, Hege G, et al.
Publicado: (2014)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status
por: Zhao, Xi, et al.
Publicado: (2014)

Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
por: Krüger, Kristi, et al.
Publicado: (2021)

Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
por: Dorraji, Esmaeil, et al.
Publicado: (2022)

eEF2K—a new target in breast cancers with combined inactivation of p53 and PTEN
por: Russnes, Hege G, et al.
Publicado: (2014)

Non-coding antisense transcription detected by conventional and single-stranded cDNA microarray
por: Vallon-Christersson, Johan, et al.
Publicado: (2007)

LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer
por: Sas‐Chen, Aldema, et al.
Publicado: (2016)

BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data
por: Saal, Lao H, et al.
Publicado: (2002)

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
por: Höglander, Elen Kristine, et al.
Publicado: (2018)

Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients
por: Gilje, Bjørnar, et al.
Publicado: (2014)

Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study
por: Nacer, Deborah F., et al.
Publicado: (2023)

ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
por: Kyte, J. A., et al.
Publicado: (2020)

Breast cancer quantitative proteome and proteogenomic landscape
por: Johansson, Henrik J., et al.
Publicado: (2019)

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
por: Røssevold, Andreas Hagen, et al.
Publicado: (2022)

Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios
por: Staaf, Johan, et al.
Publicado: (2008)

Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns
por: Holm, Karolina, et al.
Publicado: (2010)

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2021)

Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome
por: Naume, B, et al.
Publicado: (2005)

Quantitative Multigene FISH on Breast Carcinomas Identifies der(1;16)(q10;p10) as an Early Event in Luminal A Tumors
por: Rye, Inga H, et al.
Publicado: (2015)

DNA Copy Number Changes in Human Malignant Fibrous Histiocytomas by Array Comparative Genomic Hybridisation
por: Kresse, Stine H., et al.
Publicado: (2010)

Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors
por: Bergholtz, Helga, et al.
Publicado: (2022)

Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays
por: Staaf, Johan, et al.
Publicado: (2008)

Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
por: Tinholt, Mari, et al.
Publicado: (2020)

Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors
por: Rye, Inga H., et al.
Publicado: (2018)

Serum copper, zinc and copper/zinc ratio in relation to survival after breast cancer diagnosis: A prospective multicenter cohort study
por: Bengtsson, Ylva, et al.
Publicado: (2023)

Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns
por: Ugalde‐Morales, Emilio, et al.
Publicado: (2020)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

Combining Gene Signatures Improves Prediction of Breast Cancer Survival
por: Zhao, Xi, et al.
Publicado: (2011)

GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
por: Trinh, Anne, et al.
Publicado: (2014)

The HER2-Encoded miR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction
por: Newie, Inga, et al.
Publicado: (2014)

Frequent miRNA-convergent fusion gene events in breast cancer
por: Persson, Helena, et al.
Publicado: (2017)

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4gg92bssikn0n1775enbvmkir2